Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | HTR6 | P50406 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587507 | 1.00 | CYP2D6 (0.52) | CYP2D6HTR6CYP1A2HTR2CHTR2B | |
| SCHEMBL3639846 | 1.00 | CYP2D6 (0.52) | CYP2D6HTR6CYP1A2HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL7462759 | 0.98 | CYP2D6 (0.51) | CYP2D6HTR6CYP1A2HTR2CHTR2B | |
| SCHEMBL28159845 | 0.91 | CYP2D6 (0.50) | CYP2D6HTR6CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL7358682 | 0.90 | CYP2D6 (0.58) | CYP2D6HTR6CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL20571470 | 0.90 | CYP2D6 (0.49) | CYP2D6HTR6CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL15904173 | 0.89 | CYP2D6 (0.57) | CYP2D6HTR6CYP1A2CYP3A4CYP2C19 | |
| Tert-Butyl Formate SCHEMBL28126240 | 0.88 | CYP2D6 (0.43) | CYP2D6HTR6CYP1A2HTR2CHTR2B | |
| Tert-Butyl Formate SCHEMBL28126239 | 0.88 | CYP2D6 (0.43) | CYP2D6HTR6CYP1A2HTR2CHTR2B | |
| SCHEMBL5740872 | 0.87 | CYP2D6 (0.54) | CYP2D6HTR6CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666871-B2 | 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1786790-B1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008029257-A2 | IMPROVED METHOD FOR PREPARING 1,3-DISUBSTITUTED PYRROLIDINE COMPOUNDS | MEDICHEM, S.A. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-08-23 | — | — | US | disclosed |
| EP-1786790-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006019833-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-0900787-B1 | PROCESS FOR PREPARING PYRROLIDINE DERIVATIVES | KANEKA CORP (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-6005119-A | Process for preparing pyrrolidine derivatives | KANEKA CORPORATION (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0900787-A1 | PROCESS FOR PREPARING PYRROLIDINE DERIVATIVES | KANEKA CORPORATION (JP) | 1999-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | HCRTR1, HRH3, HCRTR2 | CYP2D6 1278/4885HTR6 135/4885CYP1A2 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.